美罗培南联合舒普深对重症肺炎患者临床症状缓解时间及炎症反应的影响分析  

Effect of Meropenem Combined with Sulperazone on Clinical Symptom Remission Time and Inflammatory Reaction in Patients with Severe Pneumonia

作　　者：伍杰 沈婷 WU Jie;SHEN Ting(Ji'an Hospital of Shanghai Oriental Hospital,Ji'an,Jiangxi 343000,China)

机构地区：[1]上海市东方医院吉安医院,江西吉安343000

出　　处：《现代诊断与治疗》2023年第14期2070-2072,共3页Modern Diagnosis and Treatment

摘　　要：目的探讨美罗培南联合舒普深对重症肺炎(SP)患者临床症状缓解时间及炎症反应的影响。方法选取2020年1月至2022年3月我院收治的79例SP患者,依据治疗方法分为对照组40例和观察组39例。对照组采用头孢哌酮钠舒巴坦钠治疗,观察组在对照组基础上加用美罗培南治疗。比较两组临床症状缓解时间、肺功能、炎症反应及不良反应。结果治疗后,观察组咳痰、发热及肺部啰音消失时间均短于对照组,差异有统计学意义(P<0.05);治疗后,两组用力肺活量(FVC)、第1 s用力呼气容积(FEV_(1))及呼气峰流速(PEF)水平均高于治疗前,且观察组水平高于对照组,差异有统计学意义(P<0.05);治疗后,两组γ-干扰素(IFN-γ)、白介素-6(IL-6)及白介素-1β(IL-1β)水平均低于治疗前,且观察组水平低于对照组,差异有统计学意义(P<0.05);两组不良反应率比较,无显著差异(P>0.05)。结论美罗培南联合舒普深可降低SP炎症反应,改善肺功能,促进临床症状缓解,且安全性高。Objectives To explore the effect of meropenem combined with sulperazone on clinical symptom remission time and inflammatory reaction in patients with severe pneumonia(SP).Methods A total of 79 patients with SP admitted to our hospital from January 2020 to March 2022 were selected and divided into control group(40 cases)and observation group(39 cases)according to the treatment methods.The control group was treated with sulperazone(cefoperazone sodium and sulbactam sodium),and the treatment group was treated with meropenem on the basis of the control group.The remission time of clinical symptoms,pulmonary function,inflammatory reaction and adverse reactions were compared between the two groups.Results The disappearance time of expectoration,fever and pulmonary rales in the treatment group were significantly shorter than that in the control group(P<0.05).After treatment,the levels of forced vital capacity(FVC),forced expiratory volume(FEV_(1))and peak expiratory flow rate(PEF)in the first second in the two groups were significantly higher than those before treatment,and the levels in the treatment group were significantly higher than those in the control group(P<0.05).After treatment,the levels of Interferon-γ(IFN-γ),Interleukin-6(IL-6)and interleukin-1β(IL-1β)in both groups were significantly lower than those before treatment,and the levels in the treatment group were significantly lower than those in the control group(P<0.05).There was no significant difference between the two groups in the rate of adverse reactions(P>0.05).Conclusions Meropenem combined with sulperazone can reduce SP inflammatory reaction,improve lung function,and promote clinical symptom relief,which has high safety.

关 键 词：重症肺炎 美罗培南 头孢哌酮钠舒巴坦钠 

分 类 号：R563.1[医药卫生—呼吸系统]